Exeltis UK Ltd
Exeltis UK Ltd is the United Kingdom subsidiary of the global InSud Pharma group, incorporated in 2013 and specialising in women’s healthcare. Focused on improving women’s health across all stages of life, Exeltis UK markets a range of prescription-only medicines in the areas of contraception, hormone replacement therapy (HRT), menopause management, and related women’s health conditions. Its UK product portfolio includes Slynd® (drospirenone), an estrogen-free progestin-only contraceptive pill; the Elleste range of HRT products (Elleste Solo, Elleste Duet); Femoston (estradiol/dydrogesterone) for menopausal symptoms; and Atenza XL (methylphenidate) for ADHD. Medical information enquiries can be directed to uk.medinfo@exeltis.com. Adverse events should be reported to the MHRA via the Yellow Card scheme at www.mhra.gov.uk/yellowcard or to Exeltis UK at pharmacovigilance.uk@exeltis.com.
How to Contact Exeltis UK Ltd
Medical Disclaimer
NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current. However, the knowledge and experience of a qualified healthcare professional should always be sought after instead of using the information on this page. Before taking any drug, you should always speak to your doctor or another qualified healthcare provider.
The information provided here about medications is subject to change and is not meant to include all uses, precautions, warnings, directions, drug interactions, allergic reactions, or negative effects. The absence of warnings or other information for a particular medication does not imply that the medication or medication combination is appropriate for all patients or for all possible purposes.
Experienced a Side Effect?
Report to Yellow Card (UK) or MedWatch (US)
